Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Cohen T, Schwarz TM, Vigant F, Gardner TJ, Hernandez RE, Lee B, et al. The Microtubule Inhibitor Podofilox Inhibits an Early Entry Step of Human Cytomegalovirus. Viruses. 2016;8(10).

Scarfò I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, et al. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood. 2016;127(2):221-32.

Goyal A, Wang Z, Przybycin CG, Yang B. Application of p16 Immunohistochemistry and RNA In Situ Hybridization in the Classification of Adenoid Basal Tumors of the Cervix. Int J Gynecol Pathol. 2016;35(1):82-91.

Barger J, Tanweer O, Liechty B, Snuderl M, Jafar JJ. Suprasellar epithelioid hemangioendothelioma: Case report and review of the literature. Surg Neurol Int. 2016;7(Suppl 23):S596-602.

Carroll VA, Lafferty MK, Marchionni L, Bryant JL, Gallo RC, Garzino-Demo A. Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice. Proc Natl Acad Sci U S A. 2016;113(46):13168-13173.

Magro CM, Nguyen GH. Keratoderma-like T cell dyscrasia: A report of 13 cases and its distinction from mycosis fungoides palmaris et plantaris. Indian J Dermatol Venereol Leprol. 2016;82(4):395-403.

Ouseph MM, Simons M, Treaba DO, Yakirevich E, Green PH, Bhagat G, et al. Fatal Sepsis in a Patient With Celiac Disease-Associated Hyposplenism. ACG Case Rep J. 2016;3(4):e140.

Penney KL, Pettersson A, Shui IM, Graff RE, Kraft P, Lis RT, et al. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. Cancer Epidemiol Biomarkers Prev. 2016;25(5):745-9.

Bohrer LR, Chaffee TS, Chuntova P, Brady NJ, Witschen PM, Kemp SE, et al. ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation. Genes Cancer. 2016;7(7-8):240-253.

Gounden V, Zhao Z. Eltrombopag interference in routine chemistry testing. Ann Clin Biochem. 2016;53(Pt 5):611-4.